An Open-label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib, Cyclophosphamide, and Dexamethasone (ICd) in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM)

被引：2
|
作者：
Dimopoulos, Meletios [1 ]
Grosicki, Sebastian [2 ]
Jedrzejczak, Wieslaw [3 ]
Nahi, Hareth [4 ]
Gruber, Astrid [4 ]
Hansson, Markus [5 ]
Byrne, Catriona [6 ]
Labotka, Richard [6 ]
Teng, Zhaoyang [6 ]
Yang, Huyuan [6 ]
Grzasko, Norbert [7 ,8 ]
Kumar, Shaji [9 ]
机构：
[1] Natl & Kapodistrian Univ Athens, Athens, Greece
[2] Silesian Med Univ Katowice, Katowice, Poland
[3] Med Univ Warsaw, Warsaw, Poland
[4] Karolinska Univ Hosp, Stockholm, Sweden
[5] Skane Univ Hosp, Lund, Sweden
[6] Millennium Pharmaceut Inc, Cambridge, MA USA
[7] Med Univ Lublin, Lublin, Poland
[8] St Johns Canc Ctr, Lublin, Poland
[9] Mayo Clin, Rochester, MN USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2017年 / 17卷
关键词：
D O I：
10.1016/j.clml.2017.07.148
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MM-135
引用
收藏
页码：S333 / S334
页数：2
相关论文
共 50 条
  • [31] Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study
    Kumar, Shaji K.
    Berdeja, Jesus G.
    Niesvizky, Ruben
    Lonial, Sagar
    Laubach, Jacob P.
    Hamadani, Mehdi
    Stewart, A. Keith
    Hari, Parameswaran
    Roy, Vivek
    Vescio, Robert
    Kaufman, Jonathan L.
    Berg, Deborah
    Liao, Eileen
    Di Bacco, Alessandra
    Estevam, Jose
    Gupta, Neeraj
    Hui, Ai-Min
    Rajkumar, Vincent
    Richardson, Paul G.
    LANCET ONCOLOGY, 2014, 15 (13): : 1503 - 1512
  • [32] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 MAIA Study
    Kumar, S. K.
    Moreau, P.
    Bahlis, N.
    Facon, T.
    Plesner, T.
    Orlowski, R. Z.
    Basu, S.
    Nahi, H.
    Hulin, C.
    Quach, H.
    Goldschmidt, H.
    O'Dwyer, M.
    Perrot, A.
    Venner, C. P.
    Weisel, K.
    Raje, N.
    Tiab, M.
    Macro, M.
    Frenzel, L.
    Leleu, X.
    Wang, G.
    Krevvata, M.
    Carson, R.
    Borgsten, F.
    Usmani, S. Z.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 183 - 184
  • [33] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study
    Kumar, Shaji K.
    Moreau, Philippe
    Bahlis, Nizar Jacques
    Facon, Thierry
    Plesner, Torben
    Orlowski, Robert Z.
    Basu, Supratik
    Nahi, Hareth
    Hulin, Cyrille
    Quach, Hang
    Goldschmidt, Hartmut
    O'Dwyer, Michael
    Perrot, Aurore
    Venner, Christopher P.
    Weisel, Katja
    Raje, Noopur
    Tiab, Mourad
    Macro, Margaret
    Frenzel, Laurent
    Leleu, Xavier
    Pei, Huiling
    Krevvata, Maria
    Carson, Robin
    Borgsten, Fredrik
    Usmani, Saad
    BLOOD, 2022, 140 : 10150 - 10153
  • [34] Phase III (IMROZ) study design: Isatuximab plus bortezomib (V), lenalidomide (R), and dexamethasone (d) vs VRd in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM).
    Orlowski, Robert Z.
    Goldschmidt, Hartmut
    Cavo, Michele
    Martin, Thomas G.
    Paux, Gautier
    Oprea, Corina
    Facon, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [35] Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM)
    Orlowski, Robert
    Facon, Thierry
    Kumar, Shaji
    Plesner, Torben
    Moreau, Philippe
    Bahlis, Nizar
    Basu, Supratik
    Nahi, Hareth
    Hulin, Cyrille
    Quach, Hang
    Goldschmidt, Hartmut
    O'Dwyer, Michael
    Perrot, Aurore
    Venner, Christopher
    Weisel, Katja
    Mace, Joseph
    Raje, Noopur
    Tiab, Mourad
    Macro, Margaret
    Frenzel, Laurent
    Leleu, Xavier
    Ahmadi, Tahamtan
    Wang, Jianping
    Van Rampelbergh, Rian
    Uhlar, Clarissa
    Tromp, Brenda
    Delioukina, Maria
    Vermeulen, Jessica
    Usmani, Saad
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S424 - S425
  • [36] Chronological age as a prognostic factor in transplant-ineligible patients with newly diagnosed Multiple Myeloma
    Garcia Ruiz, Raquel
    Meseguer Martinez, Elena
    Navarro Vicente, Irene
    Jimenez Castillo, Maria
    Orti Verdet, Maria Consejo
    Frances Aracil, Eva
    Arnao Herraiz, Mario
    Cortes Ortega, Omara Samantha
    Solves Alcaina, Pilar
    Cejalvo Andujar, Maria Jose
    Andreu de la Piedra, Rafael
    Garcia Feria, Ana
    Ribas Garcia, Maria Paz
    de la Rubia, Javier
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S126 - S126
  • [37] Daratumumab plus Bortezomib/Lenalidomide/ Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
    Usmani, Saad Z.
    Facon, Thierry
    Hungria, Vania
    Bahlis, Nizar J.
    Venner, Christopher P.
    Braunstein, Marc
    Pour, Ludek
    Marti, Josep
    Basu, Supratik
    Cohen, Yael C.
    Matsumoto, Morio
    Suzuki, Kenshi
    Hulin, Cyrille
    Grosicki, Sebastian
    Legiec, Wojciech
    Beksac, Meral
    Maiolino, Angelo
    Liu, Weiping
    Wang, Jianping
    Krevvata, Maria
    Lopez-Masi, Lorena
    Carey, Jodi
    Rowe, Melissa
    Carson, Robin
    Zweegman, Sonja
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S288 - S289
  • [38] Iberdomide, bortezomib, and dexamethasone (IberVd) in transplant-ineligible newly diagnosed multiple myeloma (NDMM): results from the CC-220-MM-001 trial
    White, Darrell
    Lipe, Brea
    Gironella Mesa, Mercedes
    Niesvizky, Ruben
    Oriol, Albert
    Sureda Balari, Anna
    Bhutani, Manisha
    Encinas, Cristina
    Khan, Abdullah
    Amatangelo, Michael
    Jin, Kexin
    Solomon, Thomas
    Hong, Kevin
    Amin, Alpesh
    Maciag, Paulo
    van de Donk, Niels
    Lonial, Sagar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S25 - S25
  • [39] An Open-Label Phase I/II Study of Carfilzomib, Bendamustine and Dexamethasone (CBD) in Newly Diagnosed Multiple Myeloma Patients
    Leng, Siyang
    Raza, Shahzad
    Assal, Amer
    Baliko, Gregory
    Gould, Julia
    Shields, Rachel K.
    Mapara, Markus Y.
    Lentzsch, Suzanne
    BLOOD, 2017, 130
  • [40] Efficacy and Safety of Ixazomib-Dexamethasone, Ixazomib-Cyclophosphamide-Dexamethasone, Ixazomib-Thalidomide-Dexamethasone and Ixazomib-Bendamustine-Dexamethasone for Elderly Newly Diagnosed Multiple Myeloma (NDMM) Patients: Analysis of the Phase II Randomized Unito-EMN10 Study
    Larocca, Alessandra
    Corradini, Paolo
    Mina, Roberto
    Cascavilla, Nicola
    Liberati, Anna Marina
    Pescosta, Norbert
    Petrucci, Maria Teresa
    Ciccone, Giovannino
    Capra, Andrea
    Patriarca, Francesca
    Scalabrini, Delia Rota
    Innao, Vanessa
    Poggiu, Marco
    Cea, Michele
    Zambello, Renato
    Baraldi, Anna
    Belotti, Angelo
    Cellini, Claudia
    Galli, Monica
    Grasso, Mariella
    Aquino, Sara
    Casaluci, Gloria Margiotta
    De Sabbata, Giovanni
    Ballanti, Stelvio
    Offidani, Massimo
    Mancuso, Katia
    Boccadoro, Mario
    Bringhen, Sara
    BLOOD, 2019, 134
12345